Free Webex Call
The global bleeding disorders treatment market is projected to witness a steady CAGR during the forecast period, 2023-2027. Factors such as the rise in the patient population base, increased healthcare expenditure by the public and private players, and growing disposable income for middle-class families drive the global bleeding disorders treatment market. The ongoing research and development activities and the increased focus of pharmaceutical companies on recombinant products are expected to create lucrative growth opportunities for the global bleeding disorders treatment market in the next five years. However, limited reimbursement and the high cost of availing of bleeding disorder treatment facilities may hinder the market growth in the forecast period.Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global bleeding disorders treatment market is segmented into drug type, disease type, distribution channel, end user, regional distribution, and competitive landscape. Based on drug type, the market is fragmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to capture the highest market share during the forecast period, 2023-2027. Their high efficiency in preventing bleeding than plasma-derived coagulation factor concentrates is expected to drive the market demand in the next five years.
North America is expected to dominate the global bleeding disorders treatment market in the forecast period. The compatibility of the population of all age groups in the United States for prophylaxis treatment is driving the market demand in the region.
The major players operating in the global bleeding disorders treatment market are Bayer AG, Pfizer Inc., Grifols S.A., Octapharma AG, Sun Pharmaceuticals Industries Ltd., Ferring Pharmaceuticals SA, Amgen Inc., Sanofi SA, Baxter International Inc., F. Hoffmann-La Roche Ltd., Takeda Pharmaceuticals Ltd., Novo Nordisk A/S, Novartis AG, Eli Lilly and Company Ltd., Gilead Sciences Inc., among others. The companies are focusing on extensive research and development activities to stay competitive in the market.
Years considered for this report:
- Historical Years: 2017 - 2020
- Base Year: 2021
- Estimated Year: 2022
- Forecast Period: 2023 - 2027
Objective of the Study:
- To analyze and forecast the market size of global bleeding disorders treatment market from 2017 to 2021.
- To estimate and forecast the market size of global bleeding disorders treatment market from 2022 to 2027 and growth rate until 2027.
- To classify and forecast global bleeding disorders treatment market based on drug type, disease type, distribution channel, end user, and regional distribution.
- To identify dominant region or segment in the global bleeding disorders treatment market.
- To identify drivers and challenges for global bleeding disorders treatment market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Global bleeding disorders treatment market.
- To identify and analyze the profile of leading players operating in Global bleeding disorders treatment market.
- To identify key sustainable strategies adopted by market players in Global bleeding disorders treatment market.
The publisher calculated the market size of Global bleeding disorders treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Bleeding disorders treatment vendors, end users, service providers and other stakeholders
- Distributers and suppliers of bleeding disorders treatment’s products and services and other stakeholders
- Organizations, forums, and alliances related to bleeding disorders treatment
- Market research and consulting firms
Report Scope:
In this report, Global bleeding disorders treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Market, By Drug Type:
- Plasma-derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Others
Market, By Disease Type:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online
Market, By End User:
- Clinics
- Hospitals
- Research Institutes
- Others
Market, By Region:
- North America
- APAC
- Europe
- MEA
- South America
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Global bleeding disorders treatment market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Bleeding Disorders Treatment Market4. Executive Summary5. Voice of Customer13. Market Trends & Developments15. Strategic Recommendations16. About the Publisher & Disclaimer
6. Global Bleeding Disorders Treatment Market Outlook
7. North America Bleeding Disorders Treatment Market Outlook
8. Europe Bleeding Disorders Treatment Market Outlook
9. Asia-Pacific Bleeding Disorders Treatment Market Outlook
10. Middle East and Africa Bleeding Disorders Treatment Market Outlook
11. South America Bleeding Disorders Treatment Market Outlook
12. Market Dynamics
14. Competitive Landscape
Companies Mentioned
- Bayer AG
- Pfizer Inc.
- Grifols S.A.
- Octapharma AG
- Sun Pharmaceuticals Industries Ltd.
- Ferring Pharmaceuticals SA
- Amgen Inc.
- Sanofi SA
- Baxter International Inc.
- F. Hoffmann-La Roche Ltd.
- Takeda Pharmaceuticals Ltd.
- Novo Nordisk A/S
- Novartis AG
- Eli Lilly and Company Ltd.
- Gilead Sciences Inc.